THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility

THCT stock jumped 4,650.00% to $0.019 in market hours on 05 Feb 2026 on the PNK exchange in the United States, driven by a swing from a prior close near $0.000. This move came with modest volume of 9,533.00 shares versus a 50-day average of 2,190.00, highlighting a low-float surge. We analyze the price action, financial profile, trading signals, and Meyka AI forecasting to outline risk and opportunity for investors in THC Therapeutics, Inc. (THCT) trading in USD on PNK

THCT stock price action and market context

THC Therapeutics, Inc. (THCT) traded at $0.019 on 05 Feb 2026 after a one-day gain of 4,650.00%, moving from an open of $0.019 and showing a day high and low at $0.019. Volume was 9,533.00, about 4.35x the average daily volume of 2,190.00, suggesting a short, sharp trade rather than broad institutional interest.

Business update: what drives THCT valuation

THC Therapeutics, Inc. operates in the Healthcare sector and develops the dHydronator herb dryer for sanitizing harvested cannabis and other botanicals; the company lists one full-time employee and is led by CEO Scott A. Cox. The business remains small, with market capitalization near $738,457.00 and limited revenue per share, so operational news or product adoption would be needed to support sustained gains.

THCT stock financials and valuation metrics

Key fundamentals show EPS -0.02 and a negative PE of -0.95, book value per share -0.1009, and enterprise value $1,529,884.00. Price averages are low: 50-day $0.000546 and 200-day $0.0002665, reflecting prior price history. These ratios indicate a distressed microcap with negative earnings and weak balance-sheet coverage.

Technicals, trading signals, and Meyka AI grade for THCT stock

Technical indicators show RSI 43.63 and ADX 29.74, while on‑balance volume is negative at -887,654.00, pointing to thin, volatile trading rather than stable accumulation. Meyka AI rates THCT with a score out of 100: 60.91 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.

Risk factors, catalysts, and trading considerations for THCT stock

Major risks include very low liquidity, negative book value, a one-person headcount, and heavy leverage signals in ratios like debt to market cap ~ 1.07, which can amplify moves. Potential catalysts are product adoption of the dHydronator, regulatory developments in cannabis processing, or corporate disclosures that increase transparency.

Short-term outlook and price targets for THCT stock

Given current dynamics, conservative near-term price targets start at $0.0005 (bear) and a base view near $0.0020 for 12 months without major catalysts; an aggressive scenario tied to product adoption could push toward $0.0200. These targets reflect microcap volatility, low float, and the gap between current trade and long-run averages.

Final Thoughts

Key takeaways for THCT stock: the move to $0.019 on PNK on 05 Feb 2026 was a concentrated, low-volume surge that exposes short-term traders to outsized volatility and wide bid-ask risk. Fundamentals show EPS -0.02, a negative PE, book value per share -0.1009, and market cap $738,457.00, underlining a microcap profile with limited operating scale. Meyka AI’s forecast model projects a yearly price of $0.00047, implying -97.51% versus the current $0.019; forecasts are model-based projections and not guarantees. For active traders, the stock may offer volatility-driven trading opportunities; for investors, the combination of weak financials, thin liquidity, and small market cap suggest a high-risk holding that likely needs clear operational catalysts to justify exposure. We monitor filings and product updates; see company site for primary disclosures and track trading metrics on Meyka’s platform for real-time monitoring. THC Therapeutics website THCT on Meyka

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.